Disc Medicine Inc
IRON79.720USD
+1.390+1.77%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.79BMarket Cap
LossP/E TTM
More Details of Disc Medicine Inc Company
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Disc Medicine Inc Info
Ticker SymbolIRON
Company nameDisc Medicine Inc
IPO dateAug 12, 2020
CEOQuisel (John D)
Number of employees84
Security typeOrdinary Share
Fiscal year-endAug 12
Address321 Arsenal Street, Suite 101
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone16176749274
Websitehttps://www.discmedicine.com/
Ticker SymbolIRON
IPO dateAug 12, 2020
CEOQuisel (John D)
Company Executives of Disc Medicine Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
--
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-63499.00%
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark Chin
Mr. Mark Chin
Independent Director
Independent Director
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. William Savage, M.D., Ph.D.
Dr. William Savage, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
--
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-63499.00%
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.43%
Access Industries, Inc.
7.46%
RA Capital Management, LP
5.90%
The Vanguard Group, Inc.
4.67%
BlackRock Institutional Trust Company, N.A.
4.49%
Other
67.05%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.43%
Access Industries, Inc.
7.46%
RA Capital Management, LP
5.90%
The Vanguard Group, Inc.
4.67%
BlackRock Institutional Trust Company, N.A.
4.49%
Other
67.05%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.95%
Investment Advisor/Hedge Fund
19.54%
Hedge Fund
15.71%
Venture Capital
11.72%
Private Equity
8.55%
Corporation
7.46%
Research Firm
2.13%
Sovereign Wealth Fund
0.90%
Individual Investor
0.43%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
358
37.59M
99.56%
-1.45M
2025Q3
341
35.08M
92.93%
-3.22M
2025Q2
344
37.34M
107.82%
+1.72M
2025Q1
342
37.53M
108.38%
+1.77M
2024Q4
318
30.70M
90.70%
-5.11M
2024Q3
302
32.06M
106.93%
-4.30M
2024Q2
292
32.17M
107.84%
+2.52M
2024Q1
275
26.60M
108.28%
-1.06M
2023Q4
248
24.37M
101.48%
-1.80M
2023Q3
211
23.78M
99.79%
-259.52K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
3.94M
10.43%
+855.03K
+27.73%
Sep 30, 2025
Access Industries, Inc.
2.81M
7.46%
-744.05K
-20.91%
Oct 20, 2025
RA Capital Management, LP
1.58M
4.18%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
1.44M
3.82%
+51.32K
+3.69%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
1.70M
4.49%
-17.33K
-1.01%
Sep 30, 2025
Atlas Venture
1.51M
4.01%
-628.74K
-29.34%
Dec 17, 2025
Frazier Life Sciences Management, L.P.
1.44M
3.81%
-216.30K
-13.07%
Sep 30, 2025
OrbiMed Advisors, LLC
1.42M
3.75%
--
--
Sep 30, 2025
Wellington Management Company, LLP
1.41M
3.74%
-22.01K
-1.54%
Sep 30, 2025
T. Rowe Price Associates, Inc.
1.30M
3.44%
-194.10K
-12.99%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ALPS Medical Breakthroughs ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
1.11%
JPMorgan Healthcare Leaders ETF
0.92%
State Street SPDR S&P Biotech ETF
0.79%
Direxion Daily S&P Biotech Bull 3X Shares
0.48%
JPMorgan Fundamental Data Science Small Core ETF
0.4%
ProShares Ultra Nasdaq Biotechnology
0.39%
Invesco Nasdaq Biotechnology ETF
0.29%
iShares Health Innovation Active ETF
0.27%
iShares Biotechnology ETF
0.18%
View more
ALPS Medical Breakthroughs ETF
Proportion1.25%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.11%
JPMorgan Healthcare Leaders ETF
Proportion0.92%
State Street SPDR S&P Biotech ETF
Proportion0.79%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.48%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.4%
ProShares Ultra Nasdaq Biotechnology
Proportion0.39%
Invesco Nasdaq Biotechnology ETF
Proportion0.29%
iShares Health Innovation Active ETF
Proportion0.27%
iShares Biotechnology ETF
Proportion0.18%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Date
Ex-dividend Date
Type
Ratio
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
